QUANTUM GENOMICS SAS-REGR (ALQGC.PA) Stock Price & Overview
EPA:ALQGC • FR0011648971
Current stock price
The current stock price of ALQGC.PA is 0.0721 EUR. Today ALQGC.PA is down by -1.77%. In the past month the price increased by 175.19%. In the past year, price decreased by -23.78%.
ALQGC.PA Key Statistics
- Market Cap
- 4.999M
- P/E
- N/A
- Fwd P/E
- 0.02
- EPS (TTM)
- -0.09
- Dividend Yield
- N/A
ALQGC.PA Stock Performance
ALQGC.PA Stock Chart
ALQGC.PA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to ALQGC.PA. When comparing the yearly performance of all stocks, ALQGC.PA is a bad performer in the overall market: 93.91% of all stocks are doing better.
ALQGC.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ALQGC.PA. ALQGC.PA may be in some trouble as it scores bad on both profitability and health.
ALQGC.PA Earnings
ALQGC.PA Forecast & Estimates
7 analysts have analysed ALQGC.PA and the average price target is 10.2 EUR. This implies a price increase of 14047.02% is expected in the next year compared to the current price of 0.0721.
For the next year, analysts expect an EPS growth of 6121.43% and a revenue growth 1744.53% for ALQGC.PA
ALQGC.PA Groups
Sector & Classification
ALQGC.PA Financial Highlights
Over the last trailing twelve months ALQGC.PA reported a non-GAAP Earnings per Share(EPS) of -0.09. The EPS increased by 87.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -84.63% | ||
| ROE | -726.18% | ||
| Debt/Equity | 4.49 |
ALQGC.PA Ownership
ALQGC.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 25.34 | 38.133B | ||
| ARGX | ARGENX SE | 25.4 | 38.12B | ||
| 22UA | BIONTECH SE-ADR | N/A | 18.515B | ||
| ABVX | ABIVAX SA | N/A | 8.129B | ||
| 2X1 | ABIVAX SA | N/A | 8.097B | ||
| GXE | GALAPAGOS NV | N/A | 1.831B | ||
| GLPG | GALAPAGOS NV | N/A | 1.827B | ||
| NANO | NANOBIOTIX | N/A | 1.328B | ||
| IVA | INVENTIVA SA | N/A | 1.098B | ||
| 6IV | INVENTIVA SA | N/A | 1.098B | ||
| PHIL | PHILOGEN SPA | 18.09 | 663.748M | ||
| XUP | GENFIT | N/A | 468.027M | ||
| GNFT | GENFIT | 832.35 | 435.275M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About ALQGC.PA
Company Profile
Quantum Genomics SA is a biopharmaceutical company, which engages in the development of therapies for cardiovascular diseases. The company is headquartered in Paris, Ile-De-France and currently employs 3 full-time employees. The company went IPO on 2009-07-28. The firm is a biopharmaceutical company dedicated to developing new therapies for unmet medical needs in cardiovascular disease, including high blood pressure and heart failure. Its main activity is in research and development of new therapies for the treatment of hypertension, BAPAI (Brain Aminopeptidase A Inhibitors) oriented in the field of cardiovascular diseases, especially high blood pressure and heart failure. The firm also co-develops products with academic teams, biotechnological research entities, and some of the pharmaceutical and bio-science companies. The firm is involved in four research programs. Quantum Genomics also collaborates with Center for Clinical Investigation 9201 APHP / INSERM of the Georges Pompidou European Hospital in Paris, among others.
Company Info
IPO: 2009-07-28
QUANTUM GENOMICS SAS-REGR
33 rue Marbeuf
Paris ILE-DE-FRANCE FR
Employees: 3
Phone: 33185347770
QUANTUM GENOMICS SAS-REGR / ALQGC.PA FAQ
What does ALQGC do?
Quantum Genomics SA is a biopharmaceutical company, which engages in the development of therapies for cardiovascular diseases. The company is headquartered in Paris, Ile-De-France and currently employs 3 full-time employees. The company went IPO on 2009-07-28. The firm is a biopharmaceutical company dedicated to developing new therapies for unmet medical needs in cardiovascular disease, including high blood pressure and heart failure. Its main activity is in research and development of new therapies for the treatment of hypertension, BAPAI (Brain Aminopeptidase A Inhibitors) oriented in the field of cardiovascular diseases, especially high blood pressure and heart failure. The firm also co-develops products with academic teams, biotechnological research entities, and some of the pharmaceutical and bio-science companies. The firm is involved in four research programs. Quantum Genomics also collaborates with Center for Clinical Investigation 9201 APHP / INSERM of the Georges Pompidou European Hospital in Paris, among others.
What is the stock price of QUANTUM GENOMICS SAS-REGR today?
The current stock price of ALQGC.PA is 0.0721 EUR. The price decreased by -1.77% in the last trading session.
Does QUANTUM GENOMICS SAS-REGR pay dividends?
ALQGC.PA does not pay a dividend.
How is the ChartMill rating for QUANTUM GENOMICS SAS-REGR?
ALQGC.PA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists ALQGC stock?
ALQGC.PA stock is listed on the Euronext Paris exchange.
Can you provide the PE ratio for ALQGC stock?
QUANTUM GENOMICS SAS-REGR (ALQGC.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.09).
What is the expected growth for ALQGC stock?
The Revenue of QUANTUM GENOMICS SAS-REGR (ALQGC.PA) is expected to grow by 1744.53% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.